CD8A and neoplasm: Moreover, the frequency of tumor‐infiltrating CD8+ T cells (CD45+CD8+) and NK cells (CD45+CD3−NK1.1+) upregulated significantly after CMGCL treatment, which was 2.57‐fold and 2.08‐fold than the control group (Figure 7J–M; Figure S6B,C, Supporting Information), indicating that CMGCL could activate anti‐tumor immune response partially.